Aquestive Therapeutics Reports Shareholder Vote Matters
Ticker: AQST · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: AQST
TL;DR
AQST held a shareholder vote on June 20th, details to follow.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on June 21, 2024, reporting on matters submitted to a vote of security holders on June 20, 2024. The filing does not detail the specific matters voted upon but indicates a formal submission to the SEC regarding these events.
Why It Matters
This filing indicates that Aquestive Therapeutics held a vote of its security holders, which could pertain to significant corporate actions or governance changes that may impact shareholders.
Risk Assessment
Risk Level: low — The filing is a procedural report on a shareholder vote without immediate financial implications or new risks disclosed.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of earliest event reported
- June 21, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 30 Technology Drive Warren, NJ 07059 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Aquestive Therapeutics' security holders on June 20, 2024?
The filing does not specify the exact matters voted upon, only that matters were submitted to a vote of security holders.
What is the significance of filing an 8-K for a vote of security holders?
An 8-K filing is required to report significant corporate events, including the outcome of shareholder votes, which can pertain to corporate governance, mergers, or other material decisions.
When was the report filed with the SEC?
The report was filed on June 21, 2024.
What is Aquestive Therapeutics' principal executive office address?
The principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.
What is the company's state of incorporation?
Aquestive Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-21 16:32:40
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20240620.htm (8-K) — 39KB
- 0001628280-24-029340.txt ( ) — 160KB
- aqst-20240620.xsd (EX-101.SCH) — 2KB
- aqst-20240620_lab.xml (EX-101.LAB) — 21KB
- aqst-20240620_pre.xml (EX-101.PRE) — 12KB
- aqst-20240620_htm.xml (XML) — 3KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. (a) Aquestive Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on June 20, 2024. (b) The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below. (1) The following director nominees were elected to serve as Class III members of the Board of Directors, to serve for a three-year term until the Company's 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nominee Votes For Votes Against Votes Abstaining Broker Non-Votes Santo J. Costa 24,888,723 — 680,370 26,244,609 Julie Krop, M.D. 21,612,732 — 3,955,911 26,244,609 Marco Taglietti, M.D. 24,940,348 — 628,295 26,244,609 (2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved. Votes For Votes Against Votes Abstaining 23,574,514 1,566,897 427,232 (3) The proposal to recommend the frequency of advisory vote on executive compensation was approved for one year. Votes For Votes Against Votes Abstaining 24,588,404 — 267,927 (4) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024 was ratified. Votes For Votes Against Votes Abstaining 50,666,378 895,258 251,616 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 21, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer